6533b827fe1ef96bd1285bb3

RESEARCH PRODUCT

Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures

Gennaro D'amicoDaniela ScimecaAmbrogio OrlandoR. OrlandoL.m. MontalbanoMario CottoneFilippo MocciaroM. Olivo

subject

medicine.medical_specialtyCrohn's diseasecrohn's diseaseendoscopic dilationstenosisSettore MED/09 - Medicina InternaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologymedicine.diseaseBalloonAsymptomaticEndoscopySurgeryStenosisBalloon dilationsmedicineBalloon dilationRadiologymedicine.symptomProspective cohort studybusiness

description

Abstract Aim To evaluate prospectively the clinical efficacy and safety of endoscopic hydrostatic balloon dilation in a consecutive cohort of symptomatic intestinal Crohn's disease strictures. Methods Between September 2003 and December 2008 we performed endoscopic balloon dilations in 37 Crohn's disease patients with 39 intestinal symptomatic strictures (4 naive and 35 postoperative). Dilations were performed using a Rigiflex through-the-scope balloon. Clinical success rate was claimed if a patient remained asymptomatic and did not require surgery or further endoscopic dilation, following technical success. Actuarial curves of clinical, endoscopic (redilation) and surgical recurrence were obtained by Kaplan–Meier method. Demographic and disease variables were related to the main outcomes. Results After a mean follow-up of 26.3 months (range, 2–61 months), the long-term global benefit rate was 89% (33/37). The 1–2–3 years cumulative symptom-free rates were respectively: 76%, 55% and 46%. Four patients were operated upon. Technical success predicts a lower rate of surgery. There were no complications related to the endoscopic procedures. Conclusions Endoscopic balloon dilation of symptomatic Crohn's disease strictures may achieve clinical benefit in many patients and is a valid alternative to surgery in the management of the disease. Dilation may be repeated in recurrent intestinal obstructions and appears safe without morbidity.

https://doi.org/10.1016/j.dld.2010.05.001